Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation

Table 2 Levels of anti-Aβ 42 antibody, Aβ 40, Aβ 42 and IL-8 in CSF or serum of the patient with CAA-ri and control subjects*

Disease		No. samples	Anti-Aβ 42 Ab level (U)	Aβ 40 (pg/mL)	Aβ 42 (pg/mL)	IL-8 (pg/mL)
CAA-ri (1 patient)	All values CSF	23	1.5 ± 0.9	1030 ± 640	72 ± 8	340 ± 330
CAA-ri (1 patient)	All values CSF	2	38 ± 24	1490 ± 327	<0.005	-
	Before oral corticosteroids CSF	12	1.9 ± 0.9^†	1130 ± 850	78 ± 101	570 ± 290^‡
	Before oral corticosteroids CSF	2	38 ± 24	1490 ± 327	<0.005	-
	After oral corticosteroids CSF	11	1.4 ± 0.4^†	920 ± 290	65 ± 69	80 ± 52^‡
Alzheimer’s disease (14 patients) CSF		14	0.8 ± 0.8	4990 ± 2080	540 ± 160	12 ± 46
Alzheimer’s disease (14 patients) CSF		10	29 ± 19	1330 ± 1040	52.7 ± 120	-
Multiple sclerosis (7 patients) CSF		7	1.2 ± 0.9	4180 ± 2080	770 ± 450	0 ± 0
Multiple sclerosis (7 patients) CSF		7	54 ± 22	683 ± 785	<0.005	-

*Data reported as mean ± SD. Ab: Antibody; Aβ: Amyloid β; CAA-ri: Cerebral amyloid angiopathy-related inflammation; CSF: Cerebrospinal fluid; IL-8: Interleukin 8.
^†Anti-Aβ 42 Ab level in CSF: difference between levels before and after oral corticosteroids, P ≤0.01.
^‡IL-8 level in CSF: difference between levels before and after oral corticosteroids, P ≤0.0005.

ISSN: 1742-2094